Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free CMRA Stock Alerts

Comera Life Sciences (CMRA) Competitors

Comera Life Sciences logo
Compare

CMRA vs. TRVN, NAVB, GNCA, ARDS, and GNCAQ

Should you buy Comera Life Sciences stock or one of its competitors? Comera Life Sciences's main competitors and comparable companies include Trevena (TRVN), Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), and Genocea Biosciences (GNCAQ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Comera Life Sciences compare to Trevena?

Comera Life Sciences (NASDAQ:CMRA) and Trevena (NASDAQ:TRVN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

Comera Life Sciences has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A
Trevena$443K0.14-$40.29M-$47.04N/A

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Trevena Neutral

Comera Life Sciences has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Trevena has a beta of -1.99, suggesting that its stock price is 299% less volatile than the broader market.

13.6% of Trevena shares are held by institutional investors. 8.9% of Comera Life Sciences shares are held by company insiders. Comparatively, 2.7% of Trevena shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Trevena N/A N/A -119.55%

Summary

Comera Life Sciences beats Trevena on 7 of the 8 factors compared between the two stocks.

How does Comera Life Sciences compare to Navidea Biopharmaceuticals?

Comera Life Sciences (NASDAQ:CMRA) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Navidea Biopharmaceuticals Neutral

Comera Life Sciences has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

Navidea Biopharmaceuticals has lower revenue, but higher earnings than Comera Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 8.9% of Comera Life Sciences shares are held by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Navidea Biopharmaceuticals beats Comera Life Sciences on 4 of the 7 factors compared between the two stocks.

How does Comera Life Sciences compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

Comera Life Sciences' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Comera Life Sciences N/A N/A N/A

Comera Life Sciences has lower revenue, but higher earnings than Genocea Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Comera Life Sciences Neutral

Genocea Biosciences has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

0.6% of Genocea Biosciences shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 8.9% of Comera Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Comera Life Sciences beats Genocea Biosciences on 6 of the 9 factors compared between the two stocks.

How does Comera Life Sciences compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Comera Life Sciences N/A N/A N/A

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Comera Life Sciences Neutral

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aridis Pharmaceuticals has a beta of 47.61, suggesting that its stock price is 4,661% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Comera Life Sciences has higher revenue and earnings than Aridis Pharmaceuticals. Aridis Pharmaceuticals is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M-$0.02N/A
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A

Summary

Comera Life Sciences beats Aridis Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Comera Life Sciences compare to Genocea Biosciences?

Comera Life Sciences (NASDAQ:CMRA) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Comera Life Sciences has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, meaning that its share price is 144% more volatile than the broader market.

Genocea Biosciences has lower revenue, but higher earnings than Comera Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A
Genocea BiosciencesN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Genocea Biosciences N/A N/A N/A

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Genocea Biosciences Neutral

Summary

Genocea Biosciences beats Comera Life Sciences on 2 of the 3 factors compared between the two stocks.

Get Comera Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMRA vs. The Competition

Export
MetricComera Life SciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3K$12.13B$7.18B$13.18B
Dividend YieldN/A2.63%2.52%19.60%
P/E Ratio0.00631.84198.7718.91
Price / SalesN/A747.00565.6979.10
Price / CashN/A84.0876.6852.75
Price / BookN/A9.1510.515.92
Net Income-$18M$2.82B$3.50B$380.90M

Comera Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
TRVN
Trevena
N/A$0.01
flat		N/A+450.0%$12K$443KN/A23
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/A-50.0%$5KN/A0.0030

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CMRA) was last updated on 10/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel